VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTER

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 关于艾滋病 描述(由申请人提供)：本申请建议佛蒙特州大学(UVM)佛蒙特州免疫和传染病中心(VCIID)继续进行第二阶段科布雷项目。在第一阶段科布雷期间，我们创建了一个由科学家和临床医生组成的多学科小组，负责微生物发病机制和对感染的免疫反应的合作研究。第一阶段的重点是实现科学上的卓越，同时在充满活力和严谨的氛围中建立一支足够多的调查人员。其中一个重要组成部分是对5名原始初级教员的指导，他们都获得了外部资金，有许多出版物和奖项，5人中有4人得到了晋升。我们还在第一阶段的最后两年增加了5名初级教员，这5名新教员中已经有4名获得了一些校外资金。此外，VCIID-COBRE还为基因组技术/生物信息学、蛋白质组学、外部专家系列研讨会、每周进行中研究论坛、务虚会、试点项目资金以及关于科学问题、拨款申请和职业发展的讲习班提供支持。由于这些项目，VCIID在第一阶段从9名创始教员发展到4所学院8个系的21名教员，发表了213篇论文(49篇来自初级教员)，获得了47,694,003美元的资助，没有Cobre(来自初级教员的8,818,374美元)，并被密歇根州立大学医学院认可为五大卓越中心之一。在第二阶段，我们将继续以上几个成功的项目，但对它们进行修改，引导教师成为一个具有协作拨款和可持续性的成熟中心中的一个高度互动的小组。新的5名初级教员将继续他们的项目1-4年。我们招聘了两名资深教员来填补我们智力上的空白，一名是黏膜免疫学，以加强我们新的疫苗试验中心，另一名是慢性感染/炎症诱导的癌症，以拓宽我们的思维，以了解慢性传染病的影响。基因组技术/生物信息学和蛋白质组学方面的核心将继续存在，增加一个新的BSL3设施核心，以满足希望研究BSL3制剂的VCIID调查人员日益增长的需求。同样在这一领域，我们将在VCIID、UVM和佛蒙特州卫生部之间建立独特的合作伙伴关系，该州将在UVM园区连接我们的包含BSL3设施的研究大楼，建造一座新的卫生部实验室大楼。这将为扩大BSL3联合设施提供空间，包括动物和选择制剂的使用。这些努力将使我们在新的POI和U19类别资助方面具有竞争力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Regarding AIDS DESCRIPTION (provided by applicant): This application proposes the Phase II COBRE continuation of the Vermont Center for Immunology and Infectious Diseases (VCIID) at the University of Vermont (UVM). During the Phase I COBRE period we created a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The keystone of Phase I was to achieve scientific excellence while building a critical mass of investigators in a vibrant and rigorous atmosphere. A significant component of this was the mentoring of 5 original junior faculty, all of whom obtained extramural funding, had numerous publications and awards, and 4 of 5 have been promoted. We also recruited 5 additional junior faculty in the final two years of Phase I. Already 4 of these 5 new faculty have obtained some extramural funding. In addition, the VCIID-COBRE provided support for cores in Genome Technologies/Bioinformatics, Proteomics, a seminar series of outside experts, a weekly Research-in- Progress forum, retreats, pilot project funding, and workshops on scientific issues, grant writing, and career development. As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence. During Phase II we will continue several of the above successful programs but modify them toward directing the faculty toward becoming a highly interactive group in a mature Center with collaborative grants and sustainability. The new 5 junior faculty will continue their projects for 1-4 additional years. Two senior faculty we be recruited to fill gaps in our intellectual repertoire, one in mucosal immunology to enhance our new Vaccine Trials Center, and the second in chronic infection/inflammation-induced cancer to broaden our thinking to the implications of chronic infectious conditions. Cores will be continued in Genome Technologies/Bioinformatics and Proteomics, with the addition of a new BSL3 facility core to accommodate the growing needs of VCIID investigators desiring to study BSL3 agents. Also in this area, we will form a unique partnership among the VCIID, UVM, and the Vermont Department of Health in which the State will build a new Department of Health laboratory building on the UVM campus attached to our research building containing the BSL3 facility. This will provide space for an expanded joint BSL3 facility to include animal and select agent use. These endeavors will position us to be competitive for new POI and U19 category grants.